PubMed چکیده/رکورد

Biological aging for the advancement of biogerontology: Between hopes and hypes.

استودیوی صوتی مقاله

پخش حرفه‌ای فارسی و انگلیسی

در حال بررسی نسخه‌های صوتی ذخیره‌شده…

صوت تولیدشده با هوش مصنوعی است. برای کاربرد علمی یا درمانی، متن و منبع اصلی را بررسی کنید.
خواندن هوشمند فارسی و انگلیسی در حال آماده‌سازی صداهای مرورگر…
تنظیم صدای طبیعی و سرعت

صداهایی که در نامشان «Natural»، «Neural» یا «Online» دیده می‌شود معمولاً طبیعی‌ترند. انتخاب صدا به صداهای نصب‌شده در ویندوز و مرورگر شما بستگی دارد.

چکیده اصلی

Population aging has intensified the search for biological measures that can explain why individuals of the same chronological age differ so markedly in health, function, resilience, and disease burden. Geroscience has provided a powerful framework by linking shared mechanisms of aging to multiple age-related conditions, but translation to clinical practice remains incomplete. Aging clocks and circulating biomarkers have improved biological-age estimation, yet prediction alone does not establish biological meaning or clinical utility. Emerging evidence instead supports a view of aging as a heterogeneous and multidimensional process shaped by organ-specific vulnerability, cumulative stress, multimorbidity, and declining resilience. The field should therefore move beyond single biomarkers and universal aging clocks toward gerodiagnostic approaches that characterize individual aging trajectories and their modifiability. Progress in gerotherapeutics will similarly require closer integration of mechanism, measurement, and intervention. The ultimate goal is not merely to quantify aging, but to identify actionable biological processes whose modification may preserve function, delay multimorbidity, and extend healthspan.

متن کامل اصلی

متن در JumpToDate ذخیره نشده است.

برای بررسی دسترسی کتابخانه‌ای یا خرید، رکورد اصلی را باز کنید.

رفتن به منبع اصلی

کلیدواژه‌ها

AgingBiomarkersGeroscienceHealthspanIntrinsic capacityResilience
در همین زیرشاخه

مقاله‌های مرتبط

PubMed2026

Pain Management in Older Adults: An Interprofessional Training Approach Assessed by Script Concordance Tests.

BACKGROUND: Optimal perioperative pain management in older adults challenges anesthesiologists due to increased drug sensitivity, altered pharmacokinetics, and limitations of pain assessment tools in cognitively impaired patients. This study evaluated whether a single 60-min structured collaborative training session between a geriatrician and a clinical pharmacist is associated with improved anesthesiologists' clinical reasoning regard…

PubMed2026

Functional Mobility as a Prognostic Marker in Geriatric Oncology: A Prospective Study Using Gait Speed.

Background and Objectives: Functional impairment is common in older adults with cancer and may influence treatment outcomes. This study aimed to evaluate the prognostic value of objectively measured functional mobility, with gait speed as the primary analytical variable, for survival, treatment response, and chemotherapy-related toxicity in geriatric cancer patients. Materials and Methods: In this single-center prospective study, 102 p…

PubMed2026

[Heatwaves and Resilience of Hospital Geriatric Care Pathways: Results of the Repeated National PUGG FLASH-HEATWAVE 2026 survey].

Extreme heat disproportionately affects frail older adults and may simultaneously disrupt hospital capacity, working conditions, and geriatric care pathways. We aimed to describe thermal conditions, capacity strain, and organizational adaptations in acute geriatric units (AGUs) during a heatwave and one week later, and to describe conditions in medical rehabilitation units (MRUs). PUGG FLASH-HEATWAVE was a repeated national observation…

PubMed2026

[Producing evidence for all: geriatric oncology and the challenge of equity in health care].

In France, nearly one third of breast cancers occur after the age of 70, yet these patients have long been underrepresented in the clinical trials that inform treatment decisions. This exclusion, rarely made explicit, became embedded in clinical practice. The ASTER 70s trial, published in The Lancet in 2025, provides new evidence. It shows that adjuvant chemotherapy does not improve overall survival in women aged 70 and older, while ex…